Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow(The University of Texas at Austin), Tanguy Y. Seiwert(Georgetown University), Shilpa Gupta(Cleveland Clinic), Barbara Burtness(Yale University), Amy Meister(Georgetown University), Chia‐Chi Lin(National Taiwan University Hospital), Ranee Mehra(University of Maryland, Baltimore), Joseph P. Eder(Yale Cancer Center), Ravit Geva(Tel Aviv Sourasky Medical Center), Raanan Berger(Tel Aviv University), Se‐Hoon Lee(Samsung Medical Center), Hyunseok Kang(Johns Hopkins University), Kei Muro(Aichi Cancer Center), Robert I. Haddad(Georgetown University), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyun Cheol Chung(Yonsei University), Bhumsuk Keam(Seoul National University), Jared Weiss(Georgetown University), Amit Mahipal(Dana-Farber Cancer Institute), Jonathan D. Cheng(Princeton University), Makoto Tahara(National Cancer Center Hospital East)
Cited by 859
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k